Status:

COMPLETED

Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)

Lead Sponsor:

iOMEDICO AG

Conditions:

Multiple Myeloma

Newly Diagnosed

Eligibility:

All Genders

18+ years

Brief Summary

MYLENE is a prospective, multicenter, NIS to evaluate the patient and HCP satisfaction of sc and iv application of daratumumab in routine clinical practice in Germany. Patients observed in this study ...

Detailed Description

Therapy options for MM are mainly dependent on the age and fitness of the patients. NDMM patients up to the age of 65-70 years in whom autologous stem cell transplantation is not indicated, anti-myelo...

Eligibility Criteria

Inclusion

  • Patients aged 18 years or older
  • Newly diagnosed multiple myeloma (NDMM) and decision for first-line treatment with daratumumab/lenalidomide/dexamethasone (DRd) according to SmPCs of daratumumab
  • Each patient must sign an informed consent form (ICF) indicating that he or she understands the purpose of the study and is willing to participate in the study
  • Willingness and ability to read, understand and complete patients' questionnaires due to the primary objective of the NIS (i.e., patient satisfaction using the Patient Satisfaction and Time Questionnaire (PatSTQ)).

Exclusion

  • Participation in an interventional clinical trial (participation in another non-Janssen sponsored NIS or registry is allowed)
  • Prior anti-myeloma therapy, with the exception of local radiation therapy or an emergency use of a short course of corticosteroids before treatment
  • Any restrictions/limitations preventing to be treated with DRd as per SmPCs of daratumumab

Key Trial Info

Start Date :

July 6 2022

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 20 2024

Estimated Enrollment :

96 Patients enrolled

Trial Details

Trial ID

NCT05284591

Start Date

July 6 2022

End Date

September 20 2024

Last Update

October 1 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centrum für Hämatologie und Onkologie Bethanien

Frankfurt am Main, Hesse, Germany, 60389